Sir, Colistin, recently reintroduced in human medicine, is one of the most important antibiotics currently used to treat severe Gram-negative bacterial infections in humans. Unfortunately, it is also extensively used in animal production, including in swine and poultry farming against Gram-negative bacterial pathogens. 1, 2 However, the extensive use of antibiotics in food-animal production has been shown to increase the risk of transferring resistant bacteria to humans. 3 In this study, we investigated the possible link between colistin-resistant Escherichia coli isolated from domesticated pigs and humans in a rural area in Laos.
In 2012, faecal samples were collected from 190 healthy individuals and 62 domesticated animals (44 free-range goats and 18 semi-free-range pigs) in Laksip, Laos (GPS coordinates of latitude: 19850 ′ 55.615 ′′ N; longitude: 102810 ′ 4.266 ′′ E). Approval was obtained from the Ministry of Health Council of Medical Sciences, National Ethics Committee for Health Research Laos, number 51/NECHR. The samples were screened for colistin-resistant E. coli using Cepacia Medium (Becton Dickinson, Heidelberg, Germany) and isolates identified using MALDI-TOF MS. Colistin and polymyxin B MICs were determined by Etest on Mueller-Hinton II agar (bioMérieux, France) and microdilution with cation-adjusted Mueller-Hinton II broth (Becton Dickinson, Le Pont de Claix, France) and interpreted using EUCAST 4 and CLSI 2014 guidelines (M100-S24), respectively. Conjugation experiments were conducted as previously described using kanamycin. 5 MLST was performed as described at http://mlst.warwick.ac.uk/ mlst/dbs/Ecoli/documents/primersColi_html. Virulence typing was performed by targeting 10 virulence genes (kpsMTII, papC, sfa/foc, afa/dra, iutA, iss, tsh, sitAP, ompT and hlyF) and isolates classified as extraintestinal pathogenic E. coli (ExPEC) according to the criteria of Johnson et al. 6 PFGE typing was performed as described previously 7 using XbaI (Invitrogen, France) and 1.2% PFGE agarose gel (Sigma). Lastly, PCR and sequencing of the pmrAB, phoPQ and mgrB genes of colistin-resistant E. coli were carried out.
Six colistin-resistant E. coli were isolated from humans, four from pigs and none from goats ( Table 1 ). All of the isolates displayed resistance to amoxicillin and trimethoprim/sulfamethoxazole (Table 1) . We did not isolate an E. coli strain that was only resistant to colistin, which may be due to the medium's composition.
All six of the E. coli isolated from humans and two from pigs belonged to novel STs ( Table 1 ). The remaining colistin-resistant E. coli from pigs, ST93 and ST117 (an emerging avian pathogenic E. coli), were both known zoonotic pathogenic strains. Interestingly, two colistin-resistant E. coli-one from a human (LH1, from a 15-year-old boy, the only household member screened) and one from a pig (P10)-both belonged to the same novel ST and displayed the same virulence and PFGE patterns ( Figure S1 , available as Supplementary data at JAC Online). Further investigation showed that the pig belonged to the boy's family and the boy (with no recent history of antibiotic usage) normally feeds the pig without wearing any protective equipment such as boots. This observation indicates a possible horizontal transmission from pig to human. The colistinresistant E. coli LH1 (from the human) had additional resistance to aminoglycosides and intermediate resistance to ciprofloxacin and was positive for aadA22 and aac(6 ′ )-Ib-cr. E. coli LH1 produced a transconjugant resistant to kanamycin, indicating that it has further acquired a mobile element bearing aminoglycoside resistance genes. Of these 10 colistin-resistant E. coli isolates, 4 (3 from humans and 1 from a pig) were classified as potential ExPEC ( Figure S1 ).
Lastly, no known mutations associated with colistin resistance were observed in pmrAB, phoPQ and mgrB from eight of the isolates, which could indicate the participation of other unknown gene(s) in polymyxin resistance in E. coli. However, two of the E. coli (LH57 and LH140) had a unique missense mutation of E375K in PhoQ. In silico analysis using PROVEAN software (http:// provean.jcvi.org/seq_submit.php) predicted the mutation as deleterious and it may thus contribute to resistance by affecting the activity of PhoQ. Moreover, mutations in PmrAB, another twocomponent system, have been linked to colistin resistance in E. coli from animals. 8 Daily subculturing of three colistin-resistant E. coli (LH1, LH57 and P10) in colistin-free Mueller -Hinton medium up to 30 passages resulted in one (P10) colistin-susceptible revertant (6 to 0.094 mg/L) at the 18th passage, indicating that colistin resistance is reversible in some E. coli strains and more stable in others.
Polymyxins, mostly in combination with other antibiotics in the form of premixes, are heavily used by farmers in South-East Asia. 2, 9 The unregulated use of polymyxins in animal farming could significantly contribute to the emergence of colistin resistance among zoonotic bacterial pathogens and such pathogens could find their way to humans. This is because antimicrobial drug use is regarded as the most powerful factor contributing to the emergence, selection and spread of antibiotic-resistant microorganisms and genes in animals and humans. 10 As an immediate priority, the use of the same classes of antibiotics used in human medicine, such as colistin, in animal production, should be restricted. Moreover, colistin has been reclassified as 'critically important' for human medicine (www.who.int/ foodsafety/publications/antimicrobials-third/en/).
Sir,
The most important threat to the future management and treatment of Neisseria gonorrhoeae infections is multidrug resistance. Resistance to ceftriaxone, the latest available first-line empirical monotherapy, is rising globally and confirmed treatment failures have been reported in several countries.
1 Therefore, dual antimicrobial therapies containing ceftriaxone and azithromycin are now the standard recommendation in Europe 2 and the USA. This dual antimicrobial therapy is also currently being considered as the standard first-line therapy in China. 4 However, several countries have reported the occurrence of isolates with high-level azithromycin resistance, 5 -7 which is defined by an MIC ≥256 mg/L. The emergence of these high-level azithromycin-resistant isolates poses a serious threat to the future efficacy of ceftriaxone and azithromycin dual antimicrobial therapy. As far as we are aware, this is the first report on the incidence and characterization of two high-level azithromycin-resistant isolates in China.
Both N. gonorrhoeae isolates were collected from patients at the Zhejiang Xiaoshan Hospital in Hangzhou, Zhejiang Province. Antimicrobial susceptibility testing of the N. gonorrhoeae isolates was performed using the agar dilution method. Both isolates showed high-level resistance to azithromycin, with MICs of 2048 mg/L. In addition, they were resistant to penicillin (MIC ¼ 256 mg/L), ciprofloxacin (MIC ¼ 16 mg/L) and tetracycline (MIC ¼ 32 mg/L), but susceptible to ceftriaxone (MIC ¼ 0.016 -0.03 mg/L), cefixime (MIC ¼ 0.03 mg/L) and spectinomycin (MIC¼ 16 mg/L). The genomes of the isolates were subsequently analysed by PCR amplification and sequencing to determine which azithromycin resistance determinants were present. Both isolates contained an A2059G mutation in loop V of all four 23S rRNA alleles encoded in the N. gonorrhoeae genome. This mutation has previously been associated with high-level azithromycin resistance of N. gonorrhoeae when present in minimally three of the four 23S rRNA alleles. 5 In addition, sequence analysis of the mtrR gene showed that both isolates contained a single base-pair deletion (A) in the 13 bp inverted repeat in the mtrR promoter and a G45D substitution
